SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
1-Year Return
18.23%
This Quarter Return
+0.83%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.45B
AUM Growth
+$173M
(+14%)
Cap. Flow
+$220M
Cap. Flow
% of AUM
15.19%
Top 10 Holdings %
Top 10 Hldgs %
47.24%
Holding
102
New
27
Increased
19
Reduced
27
Closed
7
Top Buys
| 1 |
Krystal Biotech
KRYS
|
$66.1M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$34.8M |
| 3 |
UroGen Pharma
URGN
|
$29.9M |
| 4 |
Elevance Health
ELV
|
$27.2M |
| 5 |
UnitedHealth
UNH
|
$26.9M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$21.7M |
| 2 |
Insmed
INSM
|
$20.3M |
| 3 |
Hologic
HOLX
|
$18.7M |
| 4 |
Merus
MRUS
|
$18.2M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$18M |
Sector Composition
| 1 | Healthcare | 99.87% |
| 2 | Consumer Staples | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
IDEAYA Biosciences
IDYA
$2.38B
| $5.26M | 0.35% |
+250,000
| New | +$5.26M |
|
52
Immunic
IMUX
$75.1M
| $5.09M | 0.34% |
7,293,007
| – | – |
|
53
QuidelOrtho
QDEL
$1.95B
| $5.01M | 0.33% |
+174,000
| New | +$5.01M |
|
54
Scholar Rock
SRRK
$3.02B
| $4.43M | 0.29% |
125,000
-160,000
| -56% | -$5.67M |
|
55
InspireMD
NSPR
$101M
| $4.28M | 0.28% |
1,886,207
+940,831
| +100% | +$2.14M |
|
56
Eton Pharmaceutcials
ETON
$474M
| $4.06M | 0.27% |
+285,000
| New | +$4.06M |
|
57
CG Oncology
CGON
$2.52B
| $4.03M | 0.27% |
155,000
-148,585
| -49% | -$3.86M |
|
58
Verastem
VSTM
$663M
| $3.88M | 0.26% |
935,909
| – | – |
|
59
ESSA Pharma
EPIX
$11M
| $3.85M | 0.25% |
2,262,026
| – | – |
|
60
Akero Therapeutics
AKRO
$3.58B
| $3.84M | 0.25% |
72,000
-45,000
| -38% | -$2.4M |
|
61
Trevi Therapeutics
TRVI
$854M
| $3.83M | 0.25% |
+700,000
| New | +$3.83M |
|
62
Tango Therapeutics
TNGX
$772M
| $3.74M | 0.25% |
+730,000
| New | +$3.74M |
|
63
Tandem Diabetes Care
TNDM
$850M
| $3.73M | 0.25% |
200,000
-296,039
| -60% | -$5.52M |
|
64
GeneDx Holdings
WGS
$3.81B
| $3.69M | 0.24% |
+40,000
| New | +$3.69M |
|
65
ANI Pharmaceuticals
ANIP
$2.07B
| $3.31M | 0.22% |
50,743
-173,941
| -77% | -$11.3M |
|
66
Mural Oncology
MURA
$35.9M
| $3.27M | 0.22% |
+1,323,877
| New | +$3.27M |
|
67
ADMA Biologics
ADMA
$4.03B
| $3.19M | 0.21% |
+175,000
| New | +$3.19M |
|
68
CytomX Therapeutics
CTMX
$376M
| $2.96M | 0.2% |
+1,304,300
| New | +$2.96M |
|
69
Orthofix Medical
OFIX
$575M
| $2.91M | 0.19% |
261,147
-340,778
| -57% | -$3.8M |
|
70
Erasca
ERAS
$457M
| $2.75M | 0.18% |
2,162,162
| – | – |
|
71
Denali Therapeutics
DNLI
$2.26B
| $2.55M | 0.17% |
182,110
+47,110
| +35% | +$659K |
|
72
Xenon Pharmaceuticals
XENE
$3.02B
| $2.47M | 0.16% |
+78,800
| New | +$2.47M |
|
|
73
Madrigal Pharmaceuticals
MDGL
$9.65B
| $2.42M | 0.16% |
8,000
-59,500
| -88% | -$18M |
|
74
Vericel Corp
VCEL
$1.72B
| $2.17M | 0.14% |
+50,953
| New | +$2.17M |
|
|
75
Merus
MRUS
$5.1B
| $2.1M | 0.14% |
40,000
-345,821
| -90% | -$18.2M |
|